Retailing giant Walgreens Boots Alliance (WBA) posted its second-quarter 2019 earnings before the bell on Tuesday, April 2.
For the quarter, sales inched 4.6% higher to $34.5 billion, while operating income slumped 23.3% to $1.5 billion.
Earnings fell 8.3% year-over-year to $1.24 per diluted share, while adjusted EPS slipped 5.4% to $1.64 in the same period.
For fiscal 2019, Walgreens now sees adjusted EPS growth to be roughly flat at constant currency rates, way lower than previous guidance of 7-12% percent growth.
“The market challenges and macro trends we have been discussing for some time accelerated, resulting in the most difficult quarter we have had since the formation of Walgreens Boots Alliance,” stressed CEO Stefano Pessina.
“During the quarter, we saw significant reimbursement pressure, compounded by lower generic deflation, as well as continued consumer market challenges in the U.S. and UK. While we had begun initiatives to address these trends, our response was not rapid enough given market conditions, resulting in a disappointing quarter that did not meet our expectations. As a result, we are now expecting roughly flat adjusted EPS growth for fiscal 2019,” he added.
Net cash provided by operating activities in the second quarter was $735 million, while free cash flow amounted to $411 million.
Sales rose 7.3% at its Retail Pharmacy USA segment to hit $26.3 billion in the second quarter — excluding the benefit from acquired Rite Aid stores, organic sales growth was merely 1.6% year-over-year.
Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q1 2024
Energy exploration company Chevron Corporation (NYSE: CVX) announced first-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation was $5.50 billion or
ABBV Earnings: AbbVie reports lower adj. profit for Q1 2024; revenue edges up
Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Friday announced first-quarter 2024 financial results, reporting a decline in adjusted earnings and a modest rise in revenues. The company reported worldwide net
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q1 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported first quarter 2024 earnings results today. Net sales increased 6.2% year-over-year to $5.06 billion. Organic sales increased 9.8%. Net income attributable to Colgate-Palmolive Company was